Efficacy and safety of direct oral anticoagulants in splanchnic vein thrombosis: a pooled analysis of literature studies.
anticoagulant agents
deep venous thrombosis
factor Xa inhibitors
splanchnic circulation
venous thromboembolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
04 Nov 2023
04 Nov 2023
Historique:
received:
16
04
2023
revised:
18
10
2023
accepted:
22
10
2023
pubmed:
6
11
2023
medline:
6
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
Limited evidence is available on management of splanchnic vein thrombosis (SVT). This study aimed to evaluate safety and efficacy of direct oral anticoagulants (DOACs) for SVT treatment. Studies were systematically searched in the PubMed, Web of Science, and Scopus databases according to PRISMA guidelines. We assessed any recanalization, full recanalization, recurrence, mortality, and major bleeding as outcomes of interest. Results were reported as weighted mean prevalence (WMP) with 95% CI. Subgroup analyses and meta-regressions have been performed to address heterogeneity and adjust for potential confounders. We included a total of 16 studies (17 datasets) on 648 patients with SVT treated with DOACs. We found any recanalization in 60.3% (95% CI: 41.8%-76.3%; I The results of the present study, mostly based on observational studies, suggest good safety and efficacy profiles of DOACs in patients with SVT. Randomized studies are needed to corroborate our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Limited evidence is available on management of splanchnic vein thrombosis (SVT).
OBJECTIVES
OBJECTIVE
This study aimed to evaluate safety and efficacy of direct oral anticoagulants (DOACs) for SVT treatment.
METHODS
METHODS
Studies were systematically searched in the PubMed, Web of Science, and Scopus databases according to PRISMA guidelines. We assessed any recanalization, full recanalization, recurrence, mortality, and major bleeding as outcomes of interest. Results were reported as weighted mean prevalence (WMP) with 95% CI. Subgroup analyses and meta-regressions have been performed to address heterogeneity and adjust for potential confounders.
RESULTS
RESULTS
We included a total of 16 studies (17 datasets) on 648 patients with SVT treated with DOACs. We found any recanalization in 60.3% (95% CI: 41.8%-76.3%; I
CONCLUSION
CONCLUSIONS
The results of the present study, mostly based on observational studies, suggest good safety and efficacy profiles of DOACs in patients with SVT. Randomized studies are needed to corroborate our findings.
Identifiants
pubmed: 37926192
pii: S1538-7836(23)00793-6
doi: 10.1016/j.jtha.2023.10.023
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests There are no competing interests to disclose.